VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
FlandersBio is undertaking international activities to assist its members. Our mission is to enhance the growth of the biotechnology industry in the international regions.
International business relations are crucial in offering the Flemish biotech companies access to international investors and pharmaceutical companies, both essential for the development and growth of our Flemish biotech companies.
FlandersBio and the American biotech cluster Bio New Jersey signed a collaboration agreement in order to attune their activities towards the life sciences sector. New Jersey is the 4th biggest biotech cluster in the US, representing more than 250 biotech companies. Read more.
Additionally, FlandersBio made a MOU with NYBA (New York Biotechnology Association) to open business opportunities between the regions. This cluster organisation has 250 members: bioscience companies, world class research institutes and related professional services. More info on www.nyba.org.
Northern Osaka is rapidly becoming one of the world’s most successful biomedical clusters (more info). The biomedical cluster in Osaka is a concentration of the world’s foremost academics and Japan’s leading pharmaceutical companies and counts more than 300 pharmaceutical companies.
International matchmaking is common practice in biotech business. Collaborations between pharmaceutical companies and innovation-driven SMEs create clear win-win opportunities. The last few years pharmaceutical companies worldwide are keen to tap into the knowledge and innovation that has been developed in Flanders.
The focus of the collaboration with the Osaka-region:
Contact us for more info about leading pharmaceutical companies in Japan.
FlandersBio is also associated with a number of European biotech cluster organisations such as CEBR and the EUROPEAN FEDERATION OF BIOTECHNOLOGY (EFB).